{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"description":"Development of graft-versus-host disease by day 100.","groups":[{"description":"Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.","id":"OG000","title":"Complement Fragment 3A - Small Cell Dose"},{"description":"Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.","id":"OG001","title":"Complement Fragment A - Larger Cell Dose"}],"paramType":"NUMBER","populationDescription":"Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.","reportingStatus":"POSTED","timeFrame":"0 to 100 days","title":"Incidence of Grades III-IV Graft-vs-host Disease","type":"SECONDARY","unitOfMeasure":"participants"}